A comprehensive international study has revealed that pine trees—long valued for their ecological and economic roles—may hold far greater medicinal potential than previously understood. The research, titled “Global Perspectives on the Medicinal Potential of Pines (Pinus spp.)”, authored by Dan Munteanu, Gabriel Murariu, Mariana Lupoae, Lucian Dinca, Danut Chira, and Andy-Stefan Popa, was published in the peer-reviewed journal Forests, on November 25, 2025.
The study presents the most extensive global review to date on the pharmacological properties of the genus Pinus. According to the findings, 86 out of approximately 120 pine species documented worldwide show evidence of medicinal value, either through traditional ethnobotanical knowledge or contemporary experimental research. The authors report that various parts of pine trees—including needles, bark, resin, buds, cones, and seeds—contain a diverse range of bioactive compounds such as polyphenols, flavonoids, terpenoids, and potent antioxidants.
Potential Therapeutic Effects
The research identifies a wide range of potential therapeutic effects. These include antioxidant, antimicrobial, anti-inflammatory, antitumor, neuroprotective, and cardiovascular benefits, as well as applications in dermatology and respiratory health.
“The exceptional phytochemical diversity found in Pinus species underscores the urgency of conserving their genetic resources and natural habitats,” lead author Dan Munteanu stated in an accompanying commentary.
He emphasized that ongoing habitat loss and climate-driven ecological changes could threaten valuable natural compounds before their medicinal potential is fully understood.
The renewed scientific interest in pine-derived compounds is supported by earlier research from major academic institutions. A study conducted by the University of California, Berkeley in 1998 identified Pycnogenol—an extract derived from the bark of the French maritime pine (Pinus pinaster)—as one of the most powerful natural antioxidants tested at the time. The UC Berkeley team found that the extract was highly effective at neutralizing free radicals, the unstable molecules linked to cellular aging and degenerative diseases.
In clinical settings, pine bark extract has shown promising results. A double-blind, randomized controlled trial involving 100 patients with stage I or II knee osteoarthritis demonstrated that taking 150 mg of Pycnogenol daily for three months significantly reduced pain levels and improved joint mobility compared with the placebo group. Published in a medical journal in 2008, the study also reported decreased reliance on non-steroidal anti-inflammatory drugs among participants receiving the pine extract.
Further evidence comes from a consolidated scientific review encompassing 39 randomized clinical trials and 2,009 participants, which evaluated Pycnogenol’s effects on multiple physiological systems. According to the review, the extract exhibited benefits for cardiovascular health, chronic venous insufficiency, joint function, skin aging, respiratory performance, and cognitive processes. The authors attributed these effects to the compound’s anti-inflammatory action, improvement of endothelial function, and support for extracellular matrix stability—mechanisms that contribute to tissue protection and repair.
From mountains to oceans, delivered to you. Follow us on Lingkar Bumi WhatsApp Channel.
Need Conservation
In an additional evaluation, researcher Gabriel Murariu reported that Pycnogenol displays chondroprotective properties, meaning it helps protect cartilage from degradation. His findings, drawn from both laboratory tests and human studies, indicate that active metabolites of procyanidins—key compounds in pine bark—are detectable in blood serum and synovial fluid after consumption. These metabolites were shown to inhibit enzymes associated with pain and inflammation. However, Murariu cautioned that long-term data and broader clinical trials are still needed to establish standardized dosing and safety guidelines.
Despite the growing body of evidence, the authors of the 2025 global review warn that many medicinal claims associated with pine species remain preliminary. Much of the existing research is limited to laboratory experiments or small-scale clinical trials. The chemical composition of pine species also varies significantly according to geography, climate, and soil conditions, posing challenges to establishing universal standards for therapeutic use.
The study highlights a critical intersection between pharmacological research and environmental conservation. Habitat loss from deforestation, urban expansion, and climate-induced stressors such as drought and pest outbreaks threaten several pine species across Europe, Asia, and North America. The authors argue that preserving pine forests is essential not only for ecosystem balance but also for protecting potential sources of future medicines.
Given these findings, health researchers and environmental organizations are calling for expanded investment in pine-related medical studies and stronger protection of pine ecosystems.
“There is a clear scientific rationale for integrating pine conservation strategies with pharmaceutical research,” the Forests paper notes. “The loss of even a single species could mean the disappearance of unique bioactive compounds with significant therapeutic value.”
As global demand for natural and plant-based medicines continues to rise, experts say pine trees may emerge as an important resource in future medical innovation. However, they warn that commercial exploitation must be tightly regulated to prevent overharvesting and ensure long-term sustainability.
The authors conclude that Pinus species represent an underexplored but highly promising group of medicinal plants. With further research, standardized extraction methods, and conservation-based policies, pine trees could contribute substantially to future treatments for inflammatory diseases, cardiovascular disorders, neurodegenerative conditions, and age-related ailments. (Wage Erlangga)
